In the Lotrel case, I think the recent KSR vs Teleflex decision (#msg-19250528) played at least some role in the judge’s denial of NVS’ request for an injunction as well as in TEVA’s decision to launch generic Lotrel at-risk.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”